Overview

Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subjects

Status:
Completed
Trial end date:
2020-11-10
Target enrollment:
Participant gender:
Summary
This is a study to assess the safety and blood levels of study drug KAE609 given in the vein.
Phase:
Phase 1
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborators:
This trial is supported in part by Wellcome Trust via Grant # Grant Number 217692/Z/19/Z
Wellcome Trust